Agape ATP Corp - ATPC Total Company Value-to-Revenue Ratio

Public company logo of Agape ATP Corp (ATPC)

IT system modernization and stable hub utilization are driving the rise in share prices for Agape ATP Corporation. The company's price-to-sales ratio demonstrates an upward trend, with the current parameter equal to -34043.48. Financial stability is based on diversified international drug distribution, although revenues remain dependent on currency fluctuations in Southeast Asia, creating certain geopolitical risks for the capital of Agape ATP Corporation.

ATPC Agape ATP: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/20/2026

agapeatpgroup.com - analytical breakdowns and key metrics (ATPC)

Fundamental company valuation:ATPC - Agape ATP Corp.
Mass-produced product of Agape ATP Corporation

This indicator reflects the real value of the operating business including tangible assets, excluding the impact of debt load on market capitalization. By analyzing the change in business value relative to revenue, an investor can see the monetization efficiency of the Agape ATP Corporation (ATPC) wellness ecosystem, where the stability of the metric is confirmed by the loyalty of longevity program participants and strict compliance with regulatory standards for dietary supplement compositions.

Competitor analysis

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|SLNO - Enterprise Value-to-Revenue Ratio|Amicus Pharma (FOLD) - Company Value to Revenue|ETNB: EV/Sales Multiple|AGIO - Total Company Value-to-Revenue Ratio|Company Value to Revenue GPCR|Enterprise Value-to-Revenue Multiple MiMedx MDXG|Enterprise Value-to-Revenue Ratio Rezolute Corp (RZLT)|Company Value to Revenue Lexicon Corp LXRX|Enterprise Value-to-Revenue Ratio MBX Biosciences, Inc. MBX|EV/Sales Multiple altimmune.com ALT|AARD - Enterprise Value-to-Revenue Ratio|Sagimet - Enterprise Value-to-Revenue Coefficient|BioAge Labs Inc. (BIOA) - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume BMEA (Biomea Fusion, Inc.)|QNCX (quincetx.com) - EV/Sales Multiple|GUTS: Business Value to Revenue|Enterprise Value-to-Revenue Ratio vtvtherapeutics.com (VTVT)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)